The FDA has been doing away with regulatory action altogether on many diagnostic health apps targeting consumers.
Business
Standard : The heart rate monitor built into the new Apple
Watch has sparked sharp debate over its risks and benefits, even
though the feature was cleared by the Food and Drug Administration.
But
out of the spotlight, the FDA has been doing away with regulatory
action altogether on many diagnostic health
apps targeting consumers, seeking to accelerate digital health
adoption by defining many of these as “low risk” medical devices.
As
the number of mobile health apps surged to a record 325,000 in 2017,
app performance is going largely unpoliced, leading to what’s been
dubbed a “Wild West” situation. Unfortunately for health
consumers, the public can’t rely on the research community to play
the role of sheriff.
When
colleagues and I recently examined the medical literature on
direct-to-consumer diagnostic apps in a study published in Diagnosis,
we repeatedly found studies marred by bias, technological naïveté
or a failure to provide crucial information for consumers. There was
also a glaring lack of studies with actual consumers to see how they
use these apps and what the impact on individual health, whether for
better or worse, might be.
The
app will see you now?
Interactive
diagnostic apps now go well beyond “Dr. Google” keyword searches.
They promise personalized information on whether a nagging symptom
can likely be relegated to self-care or whether a visit to the
doctor’s office or even the emergency room may be needed. Some of
these apps become so popular that they have been downloaded tens of
millions of times.
To
understand whether the promising nature of these apps is backed up by
the evidence, we searched both the peer-reviewed literature and
nonacademic sources. The disturbing unreliability of that evidence
for the average consumer is starkly visible when you consider apps
that “advise” (a carefully chosen word) whether you might have
skin cancer.
There
are hundreds of cancer-related apps. Perhaps because melanoma rates
have been rising for decades and it’s one of the most common young
adult cancers, the largest group of articles we found focused on
dermatology apps. One of the most prominent is Skin Scan.
If
you’re a physician or reasonably savvy consumer, Google Scholar
provides the easiest access to evidence-based information. One of the
first results that pops up is a 2013 article entitled, “Skin Scan:
A demonstration of the need for FDA regulation of medical apps on
iPhone.” If that title suggests a certain lack of objectivity, the
problem isn’t limited to dermatology. We also found an orthopedist
examining whether a symptom checker could “guess” the right
diagnosis, and an ear, nose and throat doctor investigating whether
an app could diagnose his own patients as well as he could... Read
More
No comments:
Post a Comment